Drug intelligence / Profile preview

IBI3004

Development stage: Discontinued
Lead developer: Innovent Biologics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IBI3004 is a bispecific antibody developed by Innovent Biologics for the treatment of solid tumors. It targets and binds to both carcinoembryonic antigen (CEA, also known as CEACAM5) and death receptor 5 (DR5, also known as TNFRSF10B) expressed on tumor cells. By clustering and activating DR5 upon binding to CEA-expressing tumor cells, IBI3004 induces apoptosis in these cancer cells. The drug is being evaluated in phase 1/2 clinical trials for patients with unresectable, locally advanced or metastatic solid tumors[1][2][3][5].

Other names: anti-CEA/anti-DR5 bispecific antibody

Targets

TNFRSF10B (DR5)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)

Beyond the preview

Go deeper on IBI3004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBI3004.

Explore the full profile